Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates

被引:0
作者
Megan A. Gibbs
Natilie A. Hosea
机构
[1] Pfizer Inc.,Clinical Pharmacokinetics and Pharmacodynamics
[2] Pfizer Inc.,Pharmacokinetics, Dynamics and Metabolism
来源
Clinical Pharmacokinetics | 2003年 / 42卷
关键词
Midazolam; Ketoconazole; Felodipine; Terfenadine; Grapefruit Juice;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this review is to evaluate the risks associated with the discovery and development of cytochrome P450 (CYP) 3A substrates.
引用
收藏
页码:969 / 984
页数:15
相关论文
共 328 条
[1]  
Pelkonen O.(1998)Inhibition and induction of human cytochrome P450 (CYP) enzymes Xenobiotica 28 1203-53
[2]  
Maenpaa J.(1998)Inhibition and induction of cytochrome P450 and the clinical implications Clin Pharmacokinet 35 361-90
[3]  
Taavitsainen P.(1998)Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver Pharmacol Rev 50 387-411
[4]  
Lin J.H.(1999)Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam J Clin Pharmacol 39 1109-25
[5]  
Lu A.Y.H.(1999)Cytochrome P450 3A4: regulation and role in drug metabolism Annu Rev Pharmacol Toxicol 39 1-17
[6]  
Ito K.(1999)Cytochrome P450 3A: ontogeny and drug disposition Clin Pharmacokinet 37 485-505
[7]  
Iwatsubo T.(2000)Sense and nonsense in the prediction of drug-drug interactions Curr Drug Metab 1 305-31
[8]  
Kanamitsu S.(2000)Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 41-57
[9]  
Yuan R.(2001)Interindividual variability in inhibition and induction of cytochrome P450 enzymes Annu Rev Pharmacol Toxicol 41 535-67
[10]  
Flockhart D.A.(1999)Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience Drug Metab Rev 31 15-28